

ARCC

Canadian Centre
for Applied Research
in Cancer Control

ARCC CONFERENCE 2015

Canada's Applied Research in Cancer Control Conference

PRELIMINARY PROGRAM

May 24 – 25, 2015 • Montréal, Québec

Hotel Bonaventure Montréal



Canadian
Cancer
Society



UNIVERSITY OF
TORONTO

Cancer Care Ontario
Action Cancer Ontario

PROGRAM AGENDA

ARCC Conference 2015 • May 24-25, 2015

Sunday, May 24, 2015


1:30pm – 3:30pm	FIRESIDE CHAT WORKSHOP Cancer Drug Funding and Access: A Fireside Chat Presented by GILLES PINEAU, MD, INESS; MONA SABHARWAL, PharmD, pCODR; and CHARLOTTE CHAMBERLAIN, MRCP
4:00pm – 5:00pm	SPEED NETWORKING
5:00pm – 7:00pm	ARCC WELCOME RECEPTION / POSTER VIEWING SESSION A Join your event hosts and fellow participants for a beverage, some light snacks and an opportunity to network in advance of the conference as well as view the first series of poster presentations being presented at the conference.

Monday, May 25, 2015

7:30am – 8:30am	REGISTRATION / BREAKFAST
8:30am – 8:35am	WELCOME FROM THE CO-DIRECTORS
8:35am – 8:40am	WELCOME FROM THE CANADIAN CANCER SOCIETY
8:40am – 10:15am	PLENARY PRESENTATION PSA Testing in Prostate Cancer Chaired by ALICE DRAGOMIR Presented by ANDREW LOBLAW, ROCCO ROSSI and FERNAND TURCOTTE
10:15am – 10:35am	NUTRITION BREAK
10:35am – 12:05pm	CONCURRENT SESSIONS A
A1	DRUG EVALUATION & POLICY MAKING
A1.1	Use Of Linked Health Administrative Data To Support Policy Change For Child Cancer Survivor Care Presented by MARY MCBRIDE
A1.2	Engaging The Public On Funding For Cancer Drugs: Results From A Public Deliberation Event On Priority Setting And Cancer Drug Funding In Vancouver, BC Presented by COLENE BENTLEY
A1.3	Cancer Formulary Recommendations In Canada - A Revealed Preferences Analysis Presented by DOMINIKA WRANIK
A1.4	An Assessment Of The Pan-Canadian Oncology Drug Review Economic Evaluations: Insights For Submitters And Reviewers Presented by LISA MASUCCI
A1.5	Managing Uncertainty In Policy Decision Making About Cancer Control: A Qualitative Study Of Canadian Policymakers Presented by MICHELLE DRIEDGER

A2 METHODOLOGY	
A2.1	Estimating Uncertainty Impact In Fixed-Value Decision Model Parameters – An Example In Genome-Guided Oral Premalignant Lesions Presented by IAN CROMWELL
A2.2	Micro-Costing Of High-Throughput Genomic Assays Using A Time-Motion Approach Presented by SARAH COSTA
A2.3	Utilizing Iterative Benefits Evaluation to Develop and Improve an Electronic Navigational Tool for Cancer Diagnostic Testing: A Model for Strategically Shaping the e-Health Landscape Presented by MELISSA KAAAN
A2.4	Integrating Care For Cancer Patients – Health Care Utilization Across Levels Of Complexity Presented by MARNIE MACKINNON
A2.5	The Protective Effects Of Social Relationships On Mortality: Is There Something Different About Cancer? Presented by JAMES IVENIUK
A3 PROSTATE CANCER	
A3.1	Castration-Resistant Prostate Cancer (CRPC): Evaluation Of The Quality Of Care And Disease Management In Real-Life Setting Presented by HALIMA LAHCENE
A3.2	Cost-Effectiveness Of Multiparametric Mri And Targeted Biopsy In Diagnosing Prostate Cancer Presented by ALICE DRAGOMIR
A3.3	Cost-Effectiveness of Prostate Cancer Management Strategies in Canada Presented by CHIRANJEEV SANYAL
A3.4	Use Of Docetaxel And Abiraterone In The Management Of Castration-Resistant Prostate Cancer In Quebec: A Real-World Cost-Effectiveness Study Presented by JOICE ROCHA
A3.5	Understanding Readmission Rates following Radical Prostatectomy Presented by JACQUELINE GREGORY
12:05pm – 12:45pm	NETWORKING LUNCH
12:45pm – 1:30pm	POSTER VIEWING SESSION B View the second series of poster presentations being presented at the conference.
1:30pm – 3:00pm	CONCURRENT SESSIONS B
B1 COSTING OF THE CANCER SYSTEM	
B1.1	Health System Costs Of The Pre-Diagnosis Phase In Neuroendocrine Tumours Presented by SIMRON SINGH
B1.2	Comparing Phase-Based Costs Of Cancer Care In British Columbia And Ontario Presented by REKA PATAKY
B1.3	Estimating The Net Costs Of Cancer Care Before And After Diagnosis For Childhood Cancer In Ontario Presented by CLAIRE DE OLIVEIRA
B1.4	Costs of Cervical Cancer Treatment: Estimates from Ontario, Canada Presented by CIARA PENDRITH
B1.5	A Time-Trend Economic Analysis Of Cancer Drug Trials Presented by SONYA CRESSMAN

B2 REAL LIFE DATA ON SCREENING, DIAGNOSIS, AND SURVIVAL	
B2.1	Breast Cancer Subtypes And Screening Mammography Sensitivity Presented by LINDA PERRON
B2.2	Using Administrative Data To Estimate Time To Breast Cancer Diagnosis And Percent Of Screen-Detected Breast Cancers – A Validation Study Presented by YAN YUAN
B2.3	Treatment Of Taxane Acute Pain Syndrome (Taps) In Patients Receiving Taxane Chemotherapy For Breast And Prostate Cancers – A Systematic Review And Network Analysis Presented by RICARDO FERNANDES
B2.4	Predictors Of Actual Survival In Resected Pancreatic Adenocarcinoma: A Population-Level Analysis Presented by DANIEL KAGEDAN
B2.5	Phase-Specific Health Care Costs Of Cervical Cancer: Estimates From A Population-Based Study Presented by NING LIU
B3 QUALITY IMPROVEMENT	
B3.1	Evaluating the Impact of PET Scanning for Lymphoma Patients: Development of the Ontario PET Lymphoma Staging Registries Presented by PAMELA MACCROSTIE
B3.2	Target Setting for Palliative Care Wait Times at Ontario Regional Cancer Centres Presented by VICTORIA ZWICKER
B3.3	Do We Need To Improve The Coordination Of Multidisciplinary Care For Patients With Head And Neck Cancer? An Investigation Of Unplanned Hospital Emergency Department Visits By Patients With Oropharyngeal Cancer In Ontario? Presented by ELIZABETH LOCKHART
B3.4	Optimizing the Design of a Population-Based Reflex Testing Program for Lynch Syndrome in Ontario: Health Care Providers' Perspectives Presented by YVONNE BOMBARD
B3.5	Thinking Differently About The Kids: An Innovative Approach to Improve Care Provided to pediatric Patients Undergoing External Beam Radiation Therapy Presented by KATHERINE JENSEN
3:00pm – 3:20pm	NUTRITION BREAK
3:20pm – 4:55pm	PLENARY PRESENTATION – Sustainability of the Cancer System Sustainability of the Cancer System Chaired by JEAN ROUSSEAU Presented by CRAIG EARLE, CHANTAL KROON and RAGHU RAJAN
4:55pm – 5:05pm	POSTER AWARDS & CLOSING REMARKS



CONFERENCE CO-CHAIRS & JUDGING COMMITTEE



ALICE DRAGOMIR – CONFERENCE CO-CHAIR

Dr. Alice Dragomir is a Medical Scientist with the McGill University Health Centre and an Assistant Professor in the Division of Urology – Department of Surgery at McGill University. Alice's research focuses on improving the manner in which health care is delivered to patients with prostate cancer, and for ways to optimize cost allocation for services. Alice joined ARCC in 2013, and has recently committed to Associate member status.



JEAN ROUSSEAU – CONFERENCE CO-CHAIR

Dr. Jean Rousseau has been a scientific manager at the Institut national de santé publique du Québec (INSPQ) since 2008. At the INSPQ, Dr. Rousseau heads the unit Analyse des politiques de dépistage et lutte contre les maladies chroniques, which is mandated by the Québec Ministry of Health and Social Services to evaluate the implementation of prenatal, newborn and cancer screening programs in Québec. Jean's current research topics include economic evaluation modalities of screening programs and costing analysis of screening practices. Jean joined ARCC in 2012, and is an ARCC Investigator.



SYLVIE LAMBERT – CHAIR, JUDGING COMMITTEE

Dr. Lambert joined McGill University from Australia where she was a National Health and Medical Research Council (NHMRC) Research Fellow at the Translational Cancer Research Unit, Ingham Institute for Applied Medical Research, University of New South Wales. Her national and international standing in the area of patient education, information-seeking, caregiver research, sustainable self-management interventions, longitudinal research, and psychometrics are evidenced by high-quality publications, including winning several prizes for these and attracting highly competitive funding. Her most significant studies have included Australia's first longitudinal caregiver well-being study, and developing a self-directed coping skills training and self-management interventions for couples facing cancer called Coping-Together. Dr. Lambert now plans to expand the reach of Coping-Together to patients and caregivers with low literacy and from culturally and linguistically diverse backgrounds.

SPEAKER BIOS



DR. CHARLOTTE CHAMBERLAIN is a public health and palliative care doctor currently working at the University of Bristol and the Bristol Royal Infirmary. Dr Chamberlain trained in Medicine at the Royal Free and University College London Medical School and intercalated a degree in Global Health. Following a Masters in Epidemiology, at the London School of Hygiene and Tropical Medicine, Dr Chamberlain has pursued a career in public health medicine in the South West region of England (2008 to present day). She is currently completing a PhD on 'access to non-curative anti-cancer therapies on the NHS' funded by the National Institute for Health Research (UK) at the University of Bristol. Her research interests, around cancer at the end of life and balancing priorities in publicly-funded health systems, have informed the on-going debate about the rationale for the Cancer Drugs Fund in England.



DR. CRAIG EARLE, MD, MSC is a medical oncologist specializing in gastrointestinal cancers at Sunnybrook's Odette Cancer Centre, the Director of Health Services Research for Cancer Care Ontario and the Ontario Institute for Cancer Research, a Professor of Medicine at the University of Toronto, and a Senior Scientist at the Institute for Clinical Evaluative Sciences. Dr. Earle originally trained and practiced in Ottawa, after which he spent 10 years between 1998 – 2008 in Boston at Harvard Medical School and the Harvard School of Public Health. While there, he was the founding Director of the Lance Armstrong Foundation Adult Survivorship Clinic at Dana-Farber Cancer Institute. He is currently Chair of the Ontario Steering Committee for Cancer Drug Programs. His personal research interests focus on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors, the effect of financial incentives on care delivery, and making linked de-identified administrative data more available for health research.



CHANTAL KROON, BSCN, MA completed her bachelor's degree in Nursing at Laval University in 1990, and a Master's degree in Medical Law and Ethics at King's College, University of London, UK, in 1993. She served primarily as a clinician working with pediatric, adult, and elderly patients at University Hospitals (Quebec and Switzerland), in community health settings, and in long-term care facilities. She also taught nursing at college and university levels. For the past fifteen years, she has held management positions in the Quebec health network and at the Quebec Ministry of Health and Social Services (MSSS). She has been in charge of provincial mandates on issues related to chronic diseases, primary care services and service trajectory for elderly within the health network, including those who accessed it through emergency departments. She is currently responsible for provincial workforce planning in nursing, as well as initial and continuous training.



DR. ANDREW LOBLAW, MD, FRCPC, MSc is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto. He received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen's University. He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from Royal College's Clinician Investigator Program all at the University of Toronto. Dr. Loblaw's clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy. Dr. Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Scientist at the Sunnybrook Research Institute. He is Medical Director for Sunnybrook International's Prostate Cancer Centres of Excellence, the North American Editor for Clinical Oncology, the Co-Chair of the American Society of Clinical Oncology's Genitourinary Advisory Group, and Co-Chair of the GU group for Cancer Care Ontario's Program in Evidence-Based Care. He has authored over 150 peer-reviewed papers and has been awarded grant funding of over \$17M.



DR. GILLES PINEAU, MD is coordinator of the INESSS Oncology Assessment Unit. He holds a bachelor's degree in engineering physics from Université Laval and a doctorate in medicine from the Université de Montréal. Cofounder of the ACTI-MENU Health Program, he served as its president and director from 1987 to 2003. For about a decade, he worked within the occupational health department of Hydro-Québec in various capacities, most notably as medical director. He has extensive experience in oncology. He was a scientific advisor for the Canadian Cancer Society, Québec Division, where he also served as president and for 10 years as a member of the board of directors. Furthermore, he served on the national board of directors of this Society. His work in the Université de Montréal Faculty of Medicine included serving as director of the family medicine program and multidisciplinary internship program. Concurrently, he headed the department of minor and major emergencies at the Hôtel-Dieu de Montréal, and was the founding president of the Clinique médicale de la Cité. A few years ago, together with a collaborating partner, he founded Le Point en Administration de la Santé et des Services Sociaux, a publication aimed at a readership made up of health care system administrators. Dr. Pineau currently chairs the publication's board of directors.



DR. RAGHU RAJAN, MD, MSc is a medical oncologist at the McGill University Health Centre with an interest in the management of colorectal cancer and genitourinary cancers, and serves as the disease site lead for lower gastrointestinal cancers at the MUHC. He is Associate Professor of Oncology and Medicine at McGill University, and chairs the Pharmacy and Therapeutics Committee of the MUHC. Dr. Rajan is a member of the Comité de l'évolution des pratiques en oncologie (CEPO) within INESSS and is also a member of the Programme de gestion thérapeutique des médicaments (PGTM), an initiative involving the five teaching hospitals in Quebec. After receiving his medical degree at the University of Manitoba and going through internship at McGill University, Dr. Rajan completed his training in internal medicine at the Mayo Graduate School of Medicine. He subsequently undertook subspecialty fellowships in haematology and medical oncology, as well as a Terry Fox research fellowship concurrent with a Master's degree in clinical epidemiology at McMaster University.



ROCCO ROSSI, BA, MA – A successful entrepreneur and business executive, champion fundraiser, and dedicated public servant, Rocco Rossi is currently President and CEO of Prostate Cancer Canada. As CEO of the Heart and Stroke Foundation – one of Canada's largest non-profit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over \$500 million in total and launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of Toronto and for MPP. Mr. Rossi has held senior positions at the Boston Consulting Group, TORSTAR, Labatt/Interbrew and MGI Software. A past board member of United Way of Greater Toronto and other charities, Mr. Rossi has been an active community builder. In fact, in 2012 he was awarded the Queen's Jubilee Medal for his Philanthropic and Community service. A dedicated adventurer, Rocco has walked the legendary Camino de Santiago 7 times, cycled the 1900 km length of Yonge Street from Rainy River to Toronto, kayaked the 500 km from Toronto to Ottawa, and climbed to Everest Base Camp. Mr. Rossi has a BA (Hons) in political science from McGill University and a Masters of Arts in politics from Princeton University. He is married to his wife of 27-years, Rhonnie, and they have a 25-year-old son, Domenic John, who attends OISE in Toronto where he is working on his Masters in Teaching.



DR. MONA SABHARWAL is the inaugural Executive Director of the pan-Canadian Oncology Drug Review (pCODR). In this leadership role, she had responsibility to implement and operationalize a new national initiative, engaging a broad spectrum of decision makers and stakeholder, establishing a new standard for how pharmaceutical HTA is conducted in Canada and leading to pCODR's successful launch in July 2011. In April 2014, she successfully implemented the operational integration of pCODR into CADTH and is now leading Phase 2 of the transfer which will be looking at policy alignment of pCODR and the Common Drug Review programs. She has worked in drug technology assessment and formulary management, in both British Columbia and Ontario, for approximately 20 years. Before joining pCODR, she was the Senior Manager for Drug Programs Management with the Ontario Ministry of Health and Long-Term Care. In this role, she had operational oversight of the drug submission and evaluation process for Ontario's public drug programs. Dr. Sabharwal is a registered pharmacist with experience in both community and hospital pharmacy practice. She has also conducted practice-based research focused on finding concrete ways to improve the delivery of pharmacist-based professional services. She obtained both her Bachelor of Science in Pharmacy and her Doctor of Pharmacy from the University of Toronto.



DR. FERNAND TURCOTTE, MD, MPH, FRCPC is professor emeritus of preventive medicine and public health at Université Laval. As a co-founder of the department of social and preventive medicine, most of his research activities have borne on the prevention of chronic diseases associated with toxic exposures either in the workplace or in the general environment. The evaluation of prevention strategies is a field to which he has made contributions. He has been involved for three decades in the shaping of public policies required to improve the protection of the health of the nation, in tobacco control and exposure to asbestos. Dr. Turcotte have completed my studies in medicine at the U of Montreal school of medicine (1967) and his Master in Public Health at Harvard University (1971). Dr. Turcotte has taught at Université Laval for all my career (1971-2005).

POSTER PRESENTATIONS AT-A-GLANCE

HEALTH SYSTEMS, SERVICE & POLICY

- 1 **Improving Patient Safety Through Standardized Pre-Printed Orders For Take-Home Chemotherapy**
Presented by **NITA LAKHANI** Pharmacist, Drug Formulary, CPQI, Cancer Care Ontario
- 2 **Health Services Utilization In The End-Of-Life Phase Of Patients Dying Of Prostate Cancer In Quebec Between 2001 and 2013**
Presented by **JASON HU** MSc Student, McGill University
- 3 **Improving The Quality And Safety Of Radiation Treatment: Implementing Radiation Oncology Peer Review At A Jurisdictional Level In Ontario**
Presented by **LINDSAY REDDEMAN** Cancer Care Ontario
- 4 **Population Based Analysis Of Breast Cancer Diagnosis In Alberta**
Presented by **YAN YUAN** University of Alberta
- 5 **Locally Advanced Colorectal Cancer – A Population-Based Study Of Factors Associated With Relative Excess Risk Of Death**
Presented by **LINDA PERRON** Médecin spécialiste, Institut national de santé publique du Québec
- 6 **Treatment Of Castration-Resistant Prostate Cancer In A Real-Life Setting In Quebec**
Presented by **JOICE ROCHA** Ph.D., Urology, Department of Surgery, McGill University Health Center
- 7 **Using Canadian Administrative Data To Understand The Interplay Between Primary And Oncology Care For Breast Cancer Patients During Pre-Diagnosis, Treatment And Survivorship: A CanIMPACT Study**
Presented by **PATTI GROOME** Professor, Queen's University
- 8 **Developing A Capacity Planning Model For Positron Emission Tomography Scans In Ontario**
Presented by **JONATHAN WANG** Cancer Care Ontario
- 9 **Examining The Use Of An Advanced Practice (AP) Radiation Therapy (RT) Role, The Clinical Specialist Radiation Therapist (CSRT) A New Model Of Care**
Presented by **MICHELLE ANG** Policy Research Analyst, Cancer Care Ontario
- 10 **Cervical Cancer Screening In Ontario's Primary Healthcare Practice Models: The Influence Of Financial Incentives**
Presented by **CIARA PENDRITH** Western University
- 11 **Providing Better Care Together: The Acute Leukemia Shared-Care Program**
Presented by **AMANDA WONG** Cancer Care Ontario
- 12 **Leveraging Competition For Quality Improvement In The Canadian Context**
Presented by **VICTORIA HAGENS** Manager, Regional Programs and Performance Management, Cancer Care Ontario
- 13 **Pilot Implementation Of Survivorship Care Plans – An Update**
Presented by **FRANCES WONG** BC Cancer Agency

HEALTH TECHNOLOGY ASSESSMENT

- 14 **Conducting Economic Evaluations To Inform Policy In Ontario: Example Of Docetaxel For Treatment Of Castrate-Sensitive Prostate Cancer**
Presented by **JACLYN BECA** Manager, Pharmacoeconomics Research Unit, Cancer Care Ontario
- 15 **pCODR Experience With Progression Free Survival In Assessing Treatment Clinical Benefit**
Presented by **ALEXANDRA CHAMBERS**
- 16 **Estimate The Clinical And Economic Impact Of Urologists' Adherence To The Follow-Up Guidelines After Radical Or Partial Nephrectomy For Localized And Locally Advanced Renal Cell Carcinoma In Canada**
Presented by **ALICE DRAGOMIR** McGill University
- 17 **A Cost-Effectiveness Analysis Of Intra-Lesional Il-2 For The Treatment Of Unresectable In-Transit Melanoma**
Presented by **JACLYN BECA** Manager, Pharmacoeconomics Research Unit, Cancer Care Ontario
- 18 **A Literature Review Of Economic Evaluations Of Smoking Cessation Programs In The Oncology Setting**
Presented by **WANRUDEE ISARANUWATCHAI** Health Economist, Cancer Care Ontario

- 19 **A Data-Driven Model To Support Health Human Resource (HHR) Prediction And Planning**
Presented by **JUNELL D'SOUZA** Planning Officer, Cancer Care Ontario
- 20 **Estimating Long-Term Cancer Costs Of Cancer Care In Ontario**
Presented by **CLAIRE DE OLIVEIRA** Independent Scientist/Health Economist, CAMH
- 21 **Resource Utilization And Costs Of Managing Patients With Advanced Metastatic Melanoma: A Population Based Study**
Presented by **NICOLE MITTMAN** HOPE Research Centre
- 22 **The Impact Of Aggressive Management And Palliative Care On Cancer Costs In The Final Month Of Life**
Presented by **NICOLE MITTMAN** HOPE Research Centre
- 23 **Generating Costing Algorithms For Oncology Drugs Using Administrative Databases**
Presented by **NICOLE MITTMAN** HOPE Research Centre
- 24 **Patient Navigation In Cancer Care: Is There Any Evidence Of Cost-Effectiveness?**
Presented by **LISA PARVIN** University of British Columbia

KNOWLEDGE TRANSLATION

- 25 **Communities Of Practice: A Model For Improving Quality Of Care In Radiation Treatment**
Presented by **ELIZABETH LOCKHART** Cancer Care Ontario
- 26 **A Mobile App For Primary Care Providers: Cancer Care Ontario's Cancer Screening App**
Presented by **ZEINAB EL-MASRI** Sr. Analyst, Cancer Care Ontario Co-Author(s): Priyanka Raj, Cancer Care Ontario / Lorna Dobi, Cancer Care Ontario / Laura Heller, Cancer Care Ontario / Dafna Carr, Cancer Care Ontario
- 27 **A Systematic Review Of The Incidence Of Taxane Acute Pain Syndrome (TAPS) In Patient Receiving Taxane-Based Chemotherapy For Breast And Prostate Cancers**
Presented by **RICARDO FERNANDES** The Ottawa Hospital Cancer Centre
- 28 **A National Rectal Cancer Quality Initiative: A Novel Approach To System Improvement**
Presented by **GUNITA MITERA** Quality Initiatives Specialist, Canadian Partnership Against Cancer
- 29 **Rethinking Clinical Trials (REACT) In Ontario: Evaluating The Feasibility Of Using An Integrated Consent Model To Compare Standard Of Care Treatments**
Presented by **MARK CLEMONS** Ottawa Hospital Research Institute
- 30 **Advancing Evidence-Based Dietary Assessment In Canada To Enhance Cancer Prevention And Survivorship Research**
Presented by **SHARON KIRKPATRICK** University of Waterloo
- 31 **Synoptic Radiology Reporting: Tool for Knowledge Translation and Exchange from Development to Implementation**
Presented by **PRIYANKA JAIN** Project Coordinator, Cancer Care Ontario
- 32 **Leveraging TRA Data To Assess Potential Asbestos Exposure In Ontario**
Presented by **SHEILA KALENGE** Occupational Cancer Research Centre

PATIENTS & FAMILIES

- 33 **Differences In Patient Quality Of Life For Leukemia Treatment Strategies**
Presented by **EMILY MCPHERSON** Health Economist, ARCC
- 34 **Preferences Of Cancer Patients On Method Of Collecting Patient Reported Outcomes Using The Edmonton Symptom Assessment System (Esas)-Distress Assessment Response Tool (DART)**
Presented by **WYANNE LAW** Medical Student, Princess Margaret Cancer Centre
- 35 **Advanced Basal Cell Carcinoma (ABCC) Patients' Health Value From Physicians' Perspective**
Presented by **POOYEH GRAILI** SMH
- 36 **A Systematic Review Of Interventions To Improve Sexual Dysfunction In Cancer Patients And Survivors**
Presented by **JACQUELINE LIBERTY** Research Associate, Cancer Care Ontario

37 **What Does Satisfaction With Wait Times Mean To Cancer Patients?**

Presented by **DANA RYAN** Memorial University of Newfoundland

38 **Preferential Access To Cancer Care? Patient Experiences Of Efforts To Reduce Wait Times**

Presented by **DANA RYAN** Memorial University of Newfoundland

39 **Information And Its Impact On Co-Survivors Of Cancer Patients**

Presented by **VIOLET D'SOUZA** University of Montreal

40 **Is More Homecare Nursing Associated With Fewer Hospitalizations At The End Of Life?: A Multi-Provincial Cancer Cohort Study**

Presented by **ERIN O'LEARY** Research Coordinator, McMaster University

41 **Sustainable Action For Improved Outcomes In Adolescents And Young Adults (AYA) With Cancer In Canada – The Canadian Task Force (TF) On AYA With Cancer: 2015 And Beyond**

Presented by **SONJA DE PAUW** Canadian Task Force on AYA Cancer

SOCIETAL VALUES & PUBLIC ENGAGEMENT

42 **Cancer Drug Shortages: System Lessons From Recent Cases**

Presented by **AMANDA CHAN** Cancer Care Ontario

43 **Inequalities In Access To Treatment On The Cancer Drugs Fund In England**

Presented by **CHARLOTTE CHAMBERLAIN** University of Bristol, School of Social and Community Medicine

44 **Awareness To Taking Action: How Did A Community Raise Awareness And Take Action On Behalf Of Workers Who Have Been Exposed To Asbestos**

Presented by **DESRE KRAMER** Staff scientist and Associate Director, Occupational Cancer Research Centre, Cancer Care Ontario

45 **Social Values In The Assessment Of Health Technologies For Childhood Cancer**

Presented by **AVRAM DENBURG** McMaster University/Hospital for Sick Children, University of Toronto
Co-Author(s): Avram Denburg, McMaster University/Hospital for Sick Children

46 **Attitude To Health Risk In The Canadian Population**

Presented by **NICK BANSBACK** Assistant Professor, University of British Columbia

47 **Identifying A "Representative Public": Recruiting For Demographic And Values Diversity For A Public Engagement Event On Priority Setting And Cancer Drug Funding In Vancouver, BC**

Presented by **DEAN REGIER** Senior Health Economist, ARCC-BCCA

48 **A Process To Identify Research Priorities In A Multi-Sector Group**

Presented by **MICHELLE REID** Cancer Prevention Centre, UBC

49 **Inequality By Race/Ethnicity In Survival Improvement Of Children With Acute Lymphoblastic Leukemia In The United States And Canada**

Presented by **LINWEI WANG** Master Student, University of Alberta, School of Public Health